Moreover, our study further identified that ATR inhibitor AZD6738 can be used as a combinational drug with oxaliplatin to overcome the chemoresistance to oxaliplatin induced by PAK6 in vitro and in vivo, providing a potential possibility for future consideration in clinical cancer treatment. The gene discussed is PAK6; the disease is cancer.